Glenmark cuts price of Covid drug FabiFlu by 27% within a month of launch

Higher yields and better scale allowed a price cut, said Company

Mumbai-based Glenmark has slashed the price of its anti-viral oral medication favipiravir by 27 per cent within a month of its launch in India. The company said it had started a post-marketing surveillance (PMS) study on its brand FabiFlu to monitor the efficacy and safety of the drug in 1,000 patients. 

A price war is expected in favipiravir, with several companies gearing up for the launch of the drug in the Indian market. Players like Strides, Cipla-BDR Pharma, Optimus Pharma (contract manufacture for local companies), Lupin are considering launching their own variants. 

On Monday, Glenmark announced a price cut of 27 per